



Anne Niezink

Anne Niezink is a radiation oncologist working at the UMCG, with special interests in hematology. She finished her medical degree in 2009 at the Radboud University Nijmegen and became a master in health care management in 2012 at the University of Twente. She continued her career as a resident in Radiation Oncology in the UMCG and Radiotherapy Institute Friesland, which she completed in 2017. During her residency she started with her PhD, under supervision of prof. dr. Hans Langendijk, dr. C.T. Muijs (UMCG), and prof. dr. Joachim Widder (Medical University of Vienna), on pulmonary toxicity after thoracic radiotherapy. Besides being part of the team that introduced proton therapy in mediastinal lymphoma patients, she is involved in clinical and preclinical research in the field of CAR T-cell therapy and especially the combination of CAR T-cell therapy and radiotherapy. She is a member of the national radiotherapy platform for hematology (LPRH), the member of the EORTC lymphoma group and the international lymphoma radiation oncology group (ILROG).